Compound: Miglustat
SMILES: O[C@H]1[C@H](O)[C@H](N(CCCC)C[C@@H]1O)CO
InChIKey: UQRORFVVSGFNRO-UTINFBMNSA-N
Synonyms: Miglustat, 72599-27-0, Zavesca, N-Butyldeoxynojirimycin, (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol, NB-DNJ, Butyldeoxynojirimycin, N-Butylmoranoline, N-butyl-1-deoxynojirimycin, BuDNJ, n-Butyl deoxynojirimycin, N-(n-Butyl)deoxynojirimycin, SC-48334, OGT-918, miglustatum, SC 48334, OPFOLDA, 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R,3r,4R,5S)-, ADN3S497AZ, N-(n-butyl)deoxy-nojirimycin, DTXSID6045618, DTXCID4025618, CHEBI:50381, 1,5-(BUTYLIMINO)-1,5-DIDEOXY-D-GLUCITOL, Yargesa, RefChem:57017, A16AX06, 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-,(2R-(2alpha,3beta,4alpha,5beta))-, 689-232-7, OGT 918, N-Butyl-DNJ, CHEMBL1029, n-Butyl dnj, MFCD00272581, Miglustat [USAN], N-Butyl-deoxynojirimycin, Vevesca, N-Butyldeoxynojirimycin;NB-DNJ;OGT918, Zavesca (TN), CAS-72599-27-0, N-Bu-DNJ, NBV, UNII-ADN3S497AZ, SC48334, Brazaves, Miglustat [USAN:INN:BAN], D-Glucitol, 1,5-(butylimino)-1,5-dideoxy-, NCGC00018140-02, 72599-27-0 (free base), Brazaves (TN), Opfolda (TN), MIGLUSTAT [INN], MIGLUSTAT [JAN], MIGLUSTAT [MI], 1,5-Dideoxy-1,5-N-butylimino-D-glucitol, GlyTouCan:G94744IV, MIGLUSTAT [VANDF], MIGLUSTAT [MART.], MIGLUSTAT [WHO-DD], N-(n-butyl)-1,5-dideoxy-1,5-imino-D-glucitol, MIGLUSTAT [EMA EPAR], Miglustat (JAN/USAN/INN), SCHEMBL246893, GTPL4841, orb1309423, MIGLUSTAT [ORANGE BOOK], BDBM18355, N-(n-Butyl)-1-deoxynojirimycin, UQRORFVVSGFNRO-UTINFBMNSA-N, GLXC-15328, HMS2090N20, G94744IV, Tox21_110830, (2R,3R,4R,5S)-1-Butyl-2-(hydroxymethyl)-3,4,5-piperidinetriol, EBC-07860, AKOS028109118, Tox21_110830_1, DB00419, MB06729, 3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-, NCGC00024452-03, NCGC00024452-04, DA-65462, HY-17020, N-(n-Butyl)-1-deoxynojirimycin min. 99%, NS00003211, N-Butyldeoxynojirimycin, film (dried in situ), D05032, P16976, AB00489939-10, Q425911, SR-01000000043, SR-01000000043-2, BRD-K33251802-001-01-3, Z2379810058, 134282-77-2
Theoretical properties:
molecular_formula: C10H21NO4
molecular_weight: 219.28 g/mol
exact_mass: 219.14705815 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 4
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 4
heavy_atom_count: 15
topological_polar_surface_area: 84.2 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 169-172 °C
solubility: Highly soluble in water (>1000 mg/mL as a free base).
Descriptions:
pubchem: Miglustat is a hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group. It has a role as an EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor and an anti-HIV agent. It is a member of piperidines and a tertiary amino compound. It is functionally related to a duvoglustat.
chebi: A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.
chembl: MIGLUSTAT is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Miglustat, sold under the brand name Zavesca among others, is a medication used to treat type I Gaucher disease and Pompe disease.
It was approved for medical use in the European Union in November 2002, and for medical use in the United States in July 2003.